{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:07:21Z","timestamp":1790021241068,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clnesp.2026.105005","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:33:12Z","timestamp":1785699192000},"page":"105005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-488X","authenticated-orcid":false,"given":"Bel\u00e9n","family":"P\u00e9rez-Pevida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Santana Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Lia\u00f1o Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Cl\u00e9rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Higueruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda D.","family":"Ballesteros-Pomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bret\u00f3n Lesmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Moreira Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2026.105005_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1210\/er.2017-00111","article-title":"Obesity pathogenesis: an endocrine society scientific statement","volume":"38","author":"Schwartz","year":"2017","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clnesp.2026.105005_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ecl.2016.04.016","article-title":"The psychosocial burden of obesity","volume":"45","author":"Sarwer","year":"2016","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.clnesp.2026.105005_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.clnesp.2026.105005_bib5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Di Angelantonio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clnesp.2026.105005_bib6","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jendso\/bvac195","article-title":"An updated approach to antiobesity pharmacotherapy: moving beyond the 5% weight loss goal","volume":"7","author":"Enright","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.clnesp.2026.105005_bib8","first-page":"17","article-title":"Latest developments and future perspectives in the field of obesity","volume":"13","author":"P\u00e9rez-Pevida","year":"2017","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.clnesp.2026.105005_bib9","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ (Can Med Assoc J)"},{"key":"10.1016\/j.clnesp.2026.105005_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03765-w","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105005_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12967-019-1787-5","article-title":"Discriminatory ability of anthropometric measurements of central fat distribution for prediction of post-prandial hyperglycaemia in patients with normal fasting glucose: the DICAMANO Study","volume":"17","author":"P\u00e9rez-Pevida","year":"2019","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.clnesp.2026.105005_bib43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/oby.22147","article-title":"High Body Adiposity Drives Glucose Intolerance and Increases Cardiovascular Risk in Normoglycemic Subjects","volume":"26","author":"P\u00e9rez-Pevida","year":"2018","journal-title":"Obesity (Silver Spring"},{"key":"10.1016\/j.clnesp.2026.105005_bib15","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.85970","article-title":"Short-term effects of tirzepatide in Obese adults: a real-world prospective study","author":"Adamidis","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.clnesp.2026.105005_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109181","article-title":"Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study","volume":"39","author":"Angelopoulos","year":"2025","journal-title":"J Diabet Complicat"},{"key":"10.1016\/j.clnesp.2026.105005_bib17","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1111\/dom.70810","article-title":"Six-month real-world effectiveness, persistence and safety of low-to-moderate dose tirzepatide in adults with obesity: a multicentre observational study","volume":"28","author":"Angelopoulos","year":"2026","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnesp.2026.105005_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.clnesp.2026.105005_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clnesp.2026.105005_bib20","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2337\/dc15-1081","article-title":"Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors' expert forum","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnesp.2026.105005_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clnesp.2026.105005_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101636","article-title":"Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States","volume":"51","author":"Hankosky","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clnesp.2026.105005_bib24","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib25","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1111\/dom.16343","article-title":"Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting","volume":"27","author":"Trinh","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnesp.2026.105005_bib26","doi-asserted-by":"crossref","DOI":"10.2196\/81912","article-title":"Semaglutide and tirzepatide in a remote weight management program: 12-month retrospective observational study","volume":"9","author":"Richards","year":"2025","journal-title":"JMIR Form Res"},{"key":"10.1016\/j.clnesp.2026.105005_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-025-03340-2","article-title":"Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes (SHAPE)","author":"Ng","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.clnesp.2026.105005_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/dom.70004","article-title":"Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic","volume":"27","author":"Samuels","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnesp.2026.105005_bib29","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.59558","article-title":"A real-world study of the effectiveness and safety of semaglutide for weight loss","author":"Tzoulis","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.clnesp.2026.105005_bib30","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnesp.2026.105005_bib31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clnesp.2026.105005_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000471488","article-title":"The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function","volume":"10","author":"Goossens","year":"2017","journal-title":"Obes Facts"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105005_bib33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clnesp.2026.105005_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamainternmed.2025.6112","article-title":"Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial","volume":"186","author":"Horn","year":"2026","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib35","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/dc25-1306","article-title":"Relationship between metabolic and histological responses in people with metabolic Dysfunction\u2013 associated steatohepatitis with and without type 2 diabetes: participant-level exploratory analysis of the SYNERGY-NASH trial with tirzepatide","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnesp.2026.105005_bib36","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1111\/dom.16508","article-title":"Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes","volume":"27","author":"Ciudin","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnesp.2026.105005_bib37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnesp.2026.105005_bib38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnesp.2026.105005_bib39","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1111\/dom.16463","article-title":"Tirzepatide and health-related quality of life in adults with obesity or overweight: results from the SURMOUNT-3 phase 3 randomized trial","volume":"27","author":"Gibble","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnesp.2026.105005_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/oby.70011","article-title":"Tirzepatide associated with improved health-related quality of life in adults with obesity or overweight in SURMOUNT-4","author":"Gibble","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.clnesp.2026.105005_bib41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/dom.70215","article-title":"Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial","volume":"28","author":"Shukla","year":"2026","journal-title":"Diabetes Obes Metabol"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726021029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726021029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:28:08Z","timestamp":1790018888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457726021029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S2405457726021029"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.105005","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.105005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}],"article-number":"105005"}}